A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia
NCT ID: NCT00845962
Last Updated: 2010-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
106 participants
INTERVENTIONAL
2009-02-28
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)
NCT02862912
Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine
NCT03862287
Cardiovascular Effects of Intrathecal Hyperbaric Prilocaine or Bupivacaine in Surgery Under Spinal Anesthesia
NCT05751148
Spinal Versus General Anesthesia for Ambulatory Anesthesia
NCT02529501
Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery
NCT05824338
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Another local anesthetic available for spinal anesthesia is 2-chloroprocaine. It has been used since many years, but some serious cases of toxicity in the 80's led to an interruption of its utilization. Those cases have been proven to be associated with the preservative agent (bisulfite) that was added and to the low pH (\<3) of the drug.
Since then, 2-chloroprocaine exists in a preservative-free formulation and has been used in thousands of patients worldwide, without any problem. The major advantage of 2-chloroprocaine is its shorter duration of action, permitting a faster recovery from anesthesia, and also permitting a faster discharge from hospital (in a context of ambulatory surgery)
The purpose of this study is to compare the efficacity and the readiness for discharge (from the recovery room, and from hospital) between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia in elective ambulatory surgeries.
Patients, after consenting for the study, will be randomly assigned to the following groups:
* spinal anesthesia with chloroprocaine 2% 40 mg (2 mL)
* spinal anesthesia with bupivacaine 0,75% 7,5 mg (1 mL)
An "executant anesthesiologist" will be responsible for performing the spinal anesthesia, with a 25 gauge Sprotte needle, at the level L2L3, L3L4 or L4L5. The "responsible anesthesiologist" will only take charge of the patient after the technique, so he stays double-blinded to the local anesthetic used. During surgery, if the patient feels pain, he may receive iv fentanyl, 25-100 µg at every 5 minutes.
Measures will start immediately after the spinal block:
Evaluation of the sensory block height (with ice):
* Every 3 minutes for 15 minutes (time to obtain a block a about T10)
* Every 5 minutes for 45 minutes (surgery)
* Every 10 minutes for 60 minutes, then every 15 minutes until the block regresses to S2 (recovery room and ambulatory surgery unit)
Evaluation of the motor block (using the Bromage scale):
* Every 3 minutes for 15 minutes
* At the beginning and at the end of the surgery
* After the surgery:every 10 minutes for 60 minutes, then every 15 minutes until the block regresses to S2 (recovery room and ambulatory surgery unit)
(Bromage scale: full flexion of feet and knee = 0; able to move knee and feet, not hip = 1; able to move feet only = 2; unable to move feet or knee = 3)
When the block will have regressed to S2, the patient will be asked to urinate. If he isn't able to urinate, this demand will be repeated every 15 minutes. (not applicable if the patient goes home with a urinary catheter)
In the context of an ambulatory surgery, the patient will go home when he will meet the usual discharge criteria. All patients will receive a phone call from the research team the day after surgery, and 7 days later, to assess their satisfaction towards the analgesia and to inquire about potential complications of the spinal anesthesia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chloroprocaine
chloroprocaine
spinal administration of chloroprocaine 2%, 40 mg (2 mL)
Bupivacaine
bupivacaine
spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
chloroprocaine
spinal administration of chloroprocaine 2%, 40 mg (2 mL)
bupivacaine
spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* urologic elective ambulatory procedure. For example:cystoscopy, circumcision,transurethral bladder tumor resection, varicocele and hydrocele surgery
* gynecologic elective ambulatory procedure. For example: hysteroscopy, vulvar ou vaginal biopsy
* general surgery elective ambulatory procedure. For example:inguinal herniorraphy, short ano-rectal procedure
Exclusion Criteria
* platelet \< 75 000
* concomitant drugs: clopidogrel (last dose \< 7 days), iv heparin, low molecular weight heparin (last dose \< 24 hours)
* neurologic disease: spinal stenosis, symptomatic lumbar herniated disc, multiple sclerosis
* liquid restriction (cardiac or renal insufficiency)
* allergy or intolerance to chloroprocaine, bupivacaine or PABA
* atypical plasma cholinesterase or deficiency
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER
Université de Montréal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Centre hospitalier de l'université de Montréal (CHUM) / University of Montreal
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Denis Roy, MD
Role: STUDY_DIRECTOR
St-Luc hospital, CHUM, University of Montreal
Luc Massicotte, MD
Role: STUDY_DIRECTOR
St-Luc Hospital, CHUM, University of Montreal
Marie-Andrée Lacasse, MD, resident
Role: PRINCIPAL_INVESTIGATOR
St-Luc hospital, CHUM, University of Montreal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St-Luc Hospital CHUM
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kouri ME, Kopacz DJ. Spinal 2-chloroprocaine: a comparison with lidocaine in volunteers. Anesth Analg. 2004 Jan;98(1):75-80. doi: 10.1213/01.ANE.0000093228.61443.EE.
Smith KN, Kopacz DJ, McDonald SB. Spinal 2-chloroprocaine: a dose-ranging study and the effect of added epinephrine. Anesth Analg. 2004 Jan;98(1):81-88. doi: 10.1213/01.ANE.0000093361.48458.6E.
Vath JS, Kopacz DJ. Spinal 2-chloroprocaine: the effect of added fentanyl. Anesth Analg. 2004 Jan;98(1):89-94. doi: 10.1213/01.ANE.0000093360.02058.ED.
Warren DT, Kopacz DJ. Spinal 2-chloroprocaine: the effect of added dextrose. Anesth Analg. 2004 Jan;98(1):95-101. doi: 10.1213/01.ANE.0000093362.95618.89.
Kopacz DJ. Spinal 2-chloroprocaine: minimum effective dose. Reg Anesth Pain Med. 2005 Jan-Feb;30(1):36-42. doi: 10.1016/j.rapm.2004.09.008.
Davis BR, Kopacz DJ. Spinal 2-chloroprocaine: the effect of added clonidine. Anesth Analg. 2005 Feb;100(2):559-565. doi: 10.1213/01.ANE.0000143381.30409.62.
Yoos JR, Kopacz DJ. Spinal 2-chloroprocaine: a comparison with small-dose bupivacaine in volunteers. Anesth Analg. 2005 Feb;100(2):566-572. doi: 10.1213/01.ANE.0000143356.17013.A1.
Gonter AF, Kopacz DJ. Spinal 2-chloroprocaine: a comparison with procaine in volunteers. Anesth Analg. 2005 Feb;100(2):573-579. doi: 10.1213/01.ANE.0000143380.36298.4A.
Yoos JR, Kopacz DJ. Spinal 2-chloroprocaine for surgery: an initial 10-month experience. Anesth Analg. 2005 Feb;100(2):553-558. doi: 10.1213/01.ANE.0000130397.38849.4A.
Casati A, Danelli G, Berti M, Fioro A, Fanelli A, Benassi C, Petronella G, Fanelli G. Intrathecal 2-chloroprocaine for lower limb outpatient surgery: a prospective, randomized, double-blind, clinical evaluation. Anesth Analg. 2006 Jul;103(1):234-8, table of contents. doi: 10.1213/01.ane.0000221441.44387.82.
Casati A, Fanelli G, Danelli G, Berti M, Ghisi D, Brivio M, Putzu M, Barbagallo A. Spinal anesthesia with lidocaine or preservative-free 2-chlorprocaine for outpatient knee arthroscopy: a prospective, randomized, double-blind comparison. Anesth Analg. 2007 Apr;104(4):959-64. doi: 10.1213/01.ane.0000258766.73612.d8.
Lacasse MA, Roy JD, Forget J, Vandenbroucke F, Seal RF, Beaulieu D, McCormack M, Massicotte L. Comparison of bupivacaine and 2-chloroprocaine for spinal anesthesia for outpatient surgery: a double-blind randomized trial. Can J Anaesth. 2011 Apr;58(4):384-91. doi: 10.1007/s12630-010-9450-x. Epub 2011 Jan 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
118046
Identifier Type: -
Identifier Source: secondary_id
HD07.007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.